Waldencast Sells Obagi Medical Business for up to $460M, Repays Debt, Refocuses on Milk Makeup
Summary
Waldencast plc is selling its Obagi Medical business for up to $460 million, including $366 million in cash, to Bridgepoint. This strategic divestiture will enable the company to repay approximately $178 million in senior debt and concentrate on its Milk Makeup brand.
Key Events
-
Sale of Obagi Medical Business
Waldencast plc has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint for an enterprise value of up to $460 million.
-
Debt Repayment and Balance Sheet Strengthening
The transaction includes a cash component of $366 million and will be used to repay approximately $178 million of outstanding senior term loan facility, significantly strengthening the company's balance sheet.
-
Strategic Refocus on Milk Makeup
The divestiture allows Waldencast to streamline its operations and focus on accelerating the global growth of its remaining brand, Milk Makeup.
-
Executive Leadership Transition
CEO Michel Brousset and Chief Growth Officer Hind Sebti will transition from Waldencast to lead Obagi Medical with Bridgepoint. Felipe Dutra, current Chairman of the Board, is expected to be appointed interim Chief Executive Officer of Waldencast.
Analysis
This divestiture is a transformative event for Waldencast, significantly strengthening its balance sheet by providing up to $460 million in consideration, including $366 million in cash, and enabling the repayment of approximately $178 million in senior debt. The transaction allows the company to streamline its operations and focus entirely on accelerating the growth of its Milk Makeup brand. The departure of the CEO and Chief Growth Officer to lead the divested business, with the appointment of an interim CEO, marks a substantial leadership transition.
At the time of this filing, WALD was trading at $1.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $171.4M. The 52-week trading range was $0.72 to $3.22. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.